Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Inventiva ( (IVA) ) just unveiled an update.
On November 17, 2025, Inventiva announced the full exercise of the underwriters’ option in its recent public offering in the United States, resulting in the issuance of an additional 5,844,155 American Depositary Shares (ADSs). This brings the total number of ADSs issued to 44,805,193, generating gross proceeds of approximately $172.5 million. The net proceeds, estimated at $161.2 million, will be used as identified in the base offering. The offering price was set at $3.85 per ADS, reflecting a slight discount from the average market price. This strategic financial move is expected to support Inventiva’s ongoing clinical trials and strengthen its market position in the biopharmaceutical industry.
The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for treating metabolic dysfunction-associated steatohepatitis (MASH). The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for MASH, a progressive chronic liver disease. Inventiva is publicly traded on Euronext Paris and the Nasdaq Global Market under the ticker symbol ‘IVA’.
Average Trading Volume: 215,590
Technical Sentiment Signal: Buy
Current Market Cap: $573.8M
See more data about IVA stock on TipRanks’ Stock Analysis page.